Tecvayli: BCMAxCD3 bispecific for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This evidence concerns the gene CD38 and plasma cell myeloma.